# SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

> **NCT03204331** · PHASE3 · COMPLETED · sponsor: **Myovant Sciences GmbH** · enrollment: 623 (actual)

## Conditions studied

- Endometriosis Related Pain

## Interventions

- **DRUG:** Relugolix
- **DRUG:** Estradiol/norethindrone acetate
- **DRUG:** Estradiol/norethindrone acetate placebo
- **DRUG:** Relugolix placebo

## Key facts

- **NCT ID:** NCT03204331
- **Lead sponsor:** Myovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-01
- **Primary completion:** 2020-04-01
- **Final completion:** 2021-05-31
- **Target enrollment:** 623 (ACTUAL)
- **Last updated:** 2021-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03204331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03204331, "SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03204331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*